c-MET (P991S)

MET · Variant type: point · HGVS: p.P991S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	98.6%	1.4%	92.73
2	Crizotinib	97.5%	2.5%	91.39
3	Gilteritinib	93.8%	6.2%	88.97
4	Tepotinib	92.1%	7.9%	99.75
5	Capmatinib	91.6%	8.4%	99.75
6	Deucravacitinib	91.4%	8.6%	98.99
7	Tivozanib	88.9%	11.1%	92.42
8	Pacritinib	67.1%	32.9%	88.64
9	Repotrectinib	60.0%	40.0%	84.21
10	Erdafitinib	59.0%	41.0%	95.71
11	Selpercatinib	54.4%	45.6%	96.72
12	Fostamatinib	54.0%	46.0%	96.74
13	Defactinib	53.7%	46.3%	92.68
14	Afatinib	51.0%	49.0%	98.50
15	Lenvatinib	49.3%	50.7%	97.74
16	Canertinib	46.4%	53.6%	96.49
17	Dabrafenib	46.2%	53.8%	94.74
18	Dacomitinib	45.6%	54.4%	97.99
19	Pazopanib	42.0%	58.0%	97.49
20	Vemurafenib	35.7%	64.3%	96.49
21	Axitinib	34.8%	65.2%	93.23
22	Sunitinib	33.5%	66.5%	91.73
23	Pexidartinib	33.4%	66.6%	99.49
24	Fedratinib	30.2%	69.8%	96.21
25	Neratinib	28.4%	71.6%	93.18

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	98.6%	—	—
Crizotinib	97.5%	—	—
Gilteritinib	93.8%	—	—
Tepotinib	92.1%	—	—
Capmatinib	91.6%	—	—
Deucravacitinib	91.4%	—	—
Tivozanib	88.9%	—	—
Pacritinib	67.1%	—	—
Repotrectinib	60.0%	—	—
Erdafitinib	59.0%	—	—
Selpercatinib	54.4%	—	—
Fostamatinib	54.0%	—	—
Defactinib	53.7%	—	—
Afatinib	51.0%	—	—
Lenvatinib	49.3%	—	—
Canertinib	46.4%	—	—
Dabrafenib	46.2%	—	—
Dacomitinib	45.6%	—	—
Pazopanib	42.0%	—	—
Vemurafenib	35.7%	—	—
Axitinib	34.8%	—	—
Sunitinib	33.5%	—	—
Pexidartinib	33.4%	—	—
Fedratinib	30.2%	—	—
Neratinib	28.4%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.8ms